ClinicalTrials.gg
CompletedNCT05399030Updated Aug 8, 2022

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

A Phase 1 interventional study of ICP-332 and Placebo in Healthy Subjects, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2021, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, parallel group, single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-332 in Healthy Subjects

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) between 18-26 kg/m2, the weight of male subject should not be less than 50 kg, and the weight of female subject should not be less than 45 kg.
  2. Age and fertility status

    1. Male or infertile female subjects who are between 18-45 years old (inclusive).
    2. Female subjects who are infertile.
    3. Male subjects and their partners must agree to use effective .

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic and other diseases, or allergic diseases.
  2. Subjects with clinically significant gastrointestinal dysfunction that may affect drug intake, transport or absorption.
  3. Acute disease state (such as nausea, vomiting, pyrexia or diarrhea, etc.) within 14 days before administration.
  4. Other situations judged by the investigator to be unsuitable to join this trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    ICP-332

    Single ascending doses of ICP-332 tablet; Multiple ascending doses of ICP-332 tablet

    Drug: ICP-332

  • Placebo comparator
    Placebo

    Single ascending doses of placebo; Multiple ascending doses of placebo

    Other: Placebo

Interventions

  • ICP-332 will be administered as tablet

  • OtherPlacebo

    Matching placebo will be administered as tablet

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-Emergent Adverse Events (AEs).

    Time frame: Baseline up to 28 days after last dose.

Secondary outcomes

  1. Change from baseline in Maximum concentration (Cmax)

    Time frame: Single ascending dose: baseline up to 72 hours; post-dose multiple ascending dose: baseline to Day 14.

  2. Change from baseline in blood cells.

    measuraments (e.g. blood biochemistry tests, hematology, coagulation tests); outcome measure (e.g. absolute blood cells count)

    Time frame: Multiple ascending dose: Baseline to 28 days.

07

Study locations

1 site
  • Jinan Central Hospital
    Jinan, 250013, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jan 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2022
First posted
Jun 1, 2022
StartActual
Aug 14, 2021
Primary completionActual
Jan 30, 2022
CompletionActual
Feb 18, 2022
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05399030
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Aug 14, 2021
Primary completion
Jan 30, 2022
Completion
Feb 18, 2022
Last update
Aug 8, 2022

Study contacts

Qing Wen
principal investigator · Jinan Central Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-332

Start the discussion